Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@marginofdanger 2 clicks

marginofdanger on X

I don't know if I fully agree with that. $CBBI trades at 0.4x for two reasons: 1) OTC listing and 2) no buyback. If there was a company sponsored buyback, it would probably trade at 0.6-0.7x and therefore the buybacks would be less accretive. Also if you look at my numbers you'll see that the projected share price in the non-buyback scenario is $16.16 in five years plus $2.50 in dividends vs. $19.10 in the buyback scenario. Pretty close. If you're a short-term holder, you want the buyback to re-rate this to 0.6-0.7x. If you want to long-term compound, it's not clear the buyback is that much better to me.
@marginofdanger 1 click

marginofdanger on X

$CBBI followers- the tables below show two scenarios assuming a sale in 5 years at 100% of TBV: 1) Investor reinvests the .50/yr dividend into more shares 2) CBBI suspends dividend and instead does a share repurchase The analysis shows that the results are roughly the same (BEFORE TAXES). The point here is to show that if you reinvest your dividend you can somewhat replicate the economics of a buyback. One assumption that is likely optimistic in the company buyback scenario is that they'd continue to be able to buy back at 0.4x TBV. If you tinker with that, the buyback is less valuable. cc: @mwphnh

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 34 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 5 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $98M
Triple S Special Situations Investing 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $269M
Guardian Research 4 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $98M
Value Investors Club

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $8.1B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 11 clicks

Monte Investments Market Brief Vol. CXXXII

CoreWeave and neocloud peers face financing pressure, but sold-out GPU capacity and rising H100 and B200 rental rates support continued AI…

MYRG $4B
Monte Independent Investment Research 8 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 255

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.